You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
李氏大藥廠(00950.HK):一季度純利2030.7萬港元 同比下降50.5%
格隆匯 05-26 16:38

格隆匯5月26日丨李氏大藥廠(00950.HK)發佈公吿,2022年第一季度,集團的收益合共為3.25億港元,較去年同季增加14.7%。第一季度錄得增長,主要受到新推出的《布累迪寧》TM以及《可益能》®及曲前列尼爾注射液等長期病患藥物貢獻的銷售額(分別上升18.0%及70.4%)帶動,抵銷了《菲普利》®等門診藥物以及《立邁青》®及《速樂涓》®等外科藥物的銷售額跌幅。今年第一季度,集團的毛利為2.16億港元,同比增長12.2%。集團的整體毛利率為66.5%,較於2021年第一季度錄得的68.0%下跌1.5個百分點,是由於銷售引進產品產生的收益佔比上升所致。公司擁有人應占溢利2030.7萬港元,同比下降50.5%,基本每股盈利3.45港仙。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account